Senior Talent Acquisition Business Partner

Opportunity

As a Senior TA Business Partner, you will be a part of a fast-paced and progressive HR team for an innovative Biotechnology company. Revolution Medicines is rapidly growing and this role will be an integral part of the organization's ability to attract top talent for the organization. In this highly visible position, the incumbent will lead full cycle recruiting services to hiring managers including conducting strategic job launches, sourcing, screening, and developing and extending offers for critical roles within Commercialization.

Required Skills, Experience and Education

• Bachelor's degree in Life Sciences, Business, Human Resources, or a related field; or an equivalent combination of education and experience.
• 12+ years of in-house/corporate recruiting experience, including at least 5 years supporting recruiting efforts within the biotechnology or pharmaceutical industry, specifically in Commercialization.
• Demonstrated ability to partner effectively with senior-level leaders and provide strategic recruiting consultation.
• Strong expertise in full-cycle recruiting and talent acquisition best practices.
• Proven success sourcing and recruiting passive candidates across a variety of functional areas.
• Excellent project management skills with the ability to manage multiple searches simultaneously while maintaining attention to detail.
• Strong communication, influencing, and stakeholder management skills.
• Ability to provide sound guidance on interview strategy, candidate assessment, and hiring decision-making.

Preferred Skills

• Minimum 5+ years of experience recruiting within Commercialization (Commercial & Medical Affairs).
• Experience supporting scientific, technical, and operational hiring within biotechnology or pharmaceutical environments.
• Proficiency with Greenhouse Applicant Tracking System (ATS).

Pay

The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is $177,000 - $221,000 USD.

Benefits

Our benefits package includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.

About the Role

Join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.